Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
2021
Giorgia Maroni | Mahmoud A. Bassal | Indira Krishnan | Chee Wai Fhu | Virginia Savova | Rapolas Zilionis | Valerie A. Maymi | Nicole Pandell | Eva Csizmadia | Junyan Zhang | Barbara Storti | Julio Castaño | Riccardo Panella | Jia Li | Corinne E. Gustafson | Sam Fox | Rachel D. Levy | Claire V. Meyerovitz | Peter J. Tramontozzi | Kimberly Vermilya | Assunta De Rienzo | Stefania Crucitta | Daniela S. Bassères | Marla Weetall | Art Branstrom | Alessandra Giorgetti | Raffaele Ciampi | Marzia Del Re | Romano Danesi | Ranieri Bizzarri | Henry Yang | Olivier Kocher | Allon M. Klein | Robert S. Welner | Raphael Bueno | Maria Cristina Magli | John G. Clohessy | Azhar Ali | Daniel G. Tenen | Elena Levantini
Maroni, Bassal, Krishnan et al. characterise human non-small cell lung cancer (NSCLC) carrying Kras-mutations by single-cell RNA sequencing. They identify a tumour-specific population that is conserved in mice and responds to the drug, PTC596, which is currently in clinical trials and may offer a potential avenue for treating aggressive NSCLC expressing mutated Kras.
显示更多 [+] 显示较少 [-]